Evidence map›Paper›PMID 36476236›Full record

ReviewCancer cell international2022

Landmarks in pancreatic cancer studies.

Fan Xu, Min Huang, Yun Bai, Xueshi Yin, Jingzhe Yan, Fangfang Liu, Jie Chen, Xiechuan Weng

Open access · goldAbstract readReview
In one paragraph

Review in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Fan Xu *Department of Public Health, Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Min Huang *Department of Physiology, Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Yun Bai *Department of Public Health, Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Xueshi YinDepartment of Clinic Medicine, Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Jingzhe YanDepartment of Abdominal Oncosurgery-2, Jilin Province Tumor Hospital, Changchun, 130012, China.
Fangfang LiuArt college, Southwest Minzu University, Chengdu, 610041, Sichuan, China.
Jie ChenDepartment of Orthopedics, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. u3540294@connect.hku.hk.
Xiechuan WengDepartment of Neuroscience, Beijing Institute of Basic Medical Sciences, Beijing, 100850, China. wengxc2000@163.com.
Chengdu Medical College · CNInstitute of Basic Medical Sciences of the Chinese Academy of Medical SciencesJilin Province Tumor Hospital · CNRuijin Hospital · CNSouthwest Minzu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a rare but fatal disease. Patients present advanced disease due to the lack of or typical symptoms when the tumor is still localized. A high-quality image processing system has been in practice to detect the pancreatic tumor and determine the possibility of surgery, and preoperative methods, such as ERCP are increasingly used to complement the staging modality. Pancreaticoduodenectomy is one of the complicated surgeries with potential morbidity. The minimally invasive pancreatic resections, both robot-assisted and laparoscopic, have become a part of standard surgical practice worldwide over the last decade. Moreover, advancements in adjuvant chemotherapy have improved the long-term outcomes in current clinical practice. The systemic conservative treatment, including targeted agents, remains the mainstay of treatment for patients with advanced disease. An increasing number of studies are focused on modulating the pancreatic tumor microenvironment to improve the efficacy of the immunotherapeutic strategies. Herein, the role of preoperative therapy, the novel surgical strategy, and individualized systemic treatment in pancreatic cancer is investigated. Also, the randomized controlled studies that have defined the neoadjuvant and surgical management of pancreatic cancer have been summarized.

Indexed as

LandmarksPancreatic cancer

Identifiers

PMID36476236
PMCPMC9730569
OpenAlexW4311283188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.